Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties? - PubMed (original) (raw)

Review

Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties?

S S Bielack et al. Eur J Cancer. 1996 Sep.

No abstract available

PubMed Disclaimer

Similar articles

• Non-pegylated liposomal doxorubicin in metastatic breast cancer patients: a valuable therapeutic option requiring caution.
  Bernardi D, Errante D, Stefani M, Salvagno L. Bernardi D, et al. Breast. 2010 Dec;19(6):549-50. doi: 10.1016/j.breast.2010.05.008. Epub 2010 Jun 9. Breast. 2010. PMID: 20542696 No abstract available.
• Heart failure in a breast cancer survivor.
  Moore S. Moore S. Oncol Nurs Forum. 2012 Mar;39(2):147-50. doi: 10.1188/12.ONF.147-150. Oncol Nurs Forum. 2012. PMID: 22374488 No abstract available.
• Doxorubicin for metastatic breast cancer: time for a change?
  Muggia F. Muggia F. Cancer Invest. 2003;21(6):967-8. doi: 10.1081/cnv-120025100. Cancer Invest. 2003. PMID: 14735701 No abstract available.
• Doxorubicin in experimental and clinical heart failure.
  Christiansen S, Autschbach R. Christiansen S, et al. Eur J Cardiothorac Surg. 2006 Oct;30(4):611-6. doi: 10.1016/j.ejcts.2006.06.024. Epub 2006 Aug 8. Eur J Cardiothorac Surg. 2006. PMID: 16901709 Review.
• The anthracycline antineoplastic drugs.
  Young RC, Ozols RF, Myers CE. Young RC, et al. N Engl J Med. 1981 Jul 16;305(3):139-53. doi: 10.1056/NEJM198107163050305. N Engl J Med. 1981. PMID: 7017406 Review. No abstract available.

Cited by

• Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP).
  Linkesch W, Weger M, Eder I, Auner HW, Pernegg C, Kraule C, Czejka MJ. Linkesch W, et al. Eur J Drug Metab Pharmacokinet. 2001 Jul-Sep;26(3):179-84. doi: 10.1007/BF03190394. Eur J Drug Metab Pharmacokinet. 2001. PMID: 11695718 Clinical Trial.
• Kinetic analysis of saturable myocardial uptake of idarubicin in rat heart: effect of doxorubicin and hypothermia.
  Kang W, Weiss M. Kang W, et al. Pharm Res. 2003 Jan;20(1):58-63. doi: 10.1023/a:1022246708326. Pharm Res. 2003. PMID: 12608537
• Ewing tumour: incidence, prognosis and treatment options.
  Paulussen M, Fröhlich B, Jürgens H. Paulussen M, et al. Paediatr Drugs. 2001;3(12):899-913. doi: 10.2165/00128072-200103120-00003. Paediatr Drugs. 2001. PMID: 11772151 Review.
• Establishment, Maintenance, and Performance of the Cooperative Osteosarcoma Study Group (COSS).
  Bielack SS, Kager L, Kühne T, Langer T, Reichardt P, Blattmann C, Kevric M, Mettmann V, Sorg B, Hecker-Nolting S. Bielack SS, et al. Cancers (Basel). 2023 Feb 28;15(5):1520. doi: 10.3390/cancers15051520. Cancers (Basel). 2023. PMID: 36900310 Free PMC article. Review.
• TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects.
  van der Veen AH, de Wilt JH, Eggermont AM, van Tiel ST, Seynhaeve AL, ten Hagen TL. van der Veen AH, et al. Br J Cancer. 2000 Feb;82(4):973-80. doi: 10.1054/bjoc.1999.1027. Br J Cancer. 2000. PMID: 10732774 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database